Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss

Maria Talantova,Sara Sanz-Blasco,Xiaofei Zhang,Peng Xia,Mohd Waseem Akhtar,Shu-ichi Okamoto,Gustavo Dziewczapolski,Tomohiro Nakamura,Gang Cao,Alexander E. Pratt,Yeon-Joo Kang,Shichun Tu,Elena Molokanova,Scott R. McKercher,Samuel Andrew Hires,Hagit Sason,David G. Stouffer,Matthew W. Buczynski,James P. Solomon,Sarah Michael,Evan T. Powers,Jeffery W. Kelly,Amanda Roberts,Gary Tong,Traci Fang-Newmeyer,James Parker,Emily A. Holland,Dongxian Zhang,Nobuki Nakanishi,H.-S. Vincent Chen,Herman Wolosker,Yuqiang Wang,Loren H. Parsons,Rajesh Ambasudhan,Eliezer Masliah,Stephen F. Heinemann,Juan C. Piña-Crespo,Stuart A. Lipton
DOI: https://doi.org/10.1073/pnas.1306832110
IF: 11.1
2013-06-17
Proceedings of the National Academy of Sciences
Abstract:Significance Communication between nerve cells occurs at specialized cellular structures known as synapses. Loss of synaptic function is associated with cognitive decline in Alzheimer’s disease (AD). However, the mechanism of synaptic damage remains incompletely understood. Here we describe a pathway for synaptic damage whereby amyloid-β 1–42 peptide (Aβ 1–42 ) releases, via stimulation of α7 nicotinic receptors, excessive amounts of glutamate from astrocytes, in turn activating extrasynaptic NMDA-type glutamate receptors (eNMDARs) to mediate synaptic damage. The Food and Drug Administration-approved drug memantine offers some beneficial effect, but the improved eNMDAR antagonist NitroMemantine completely ameliorates Aβ-induced synaptic loss, providing hope for disease-modifying intervention in AD.
What problem does this paper attempt to address?